文献速递骨软组织肉瘤与黑色素瘤

帕博利珠单抗或安慰剂治疗III期黑色素瘤中免疫相关不良事件与无复发生存的相关性:随机临床试验的二次分析

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究基于双盲EORTC 1325/KEYNOTE-054试验,纳入1019例高危III期黑色素瘤患者,随机接受帕博利珠单抗或安慰剂治疗。结果显示,帕博利珠单抗组免疫相关不良事件发生率为37.4%,安慰剂组为9.0%;

要点

  • 帕博利珠单抗组irAE发生率37.4%,安慰剂组9.0%。

核心结论

  • 在帕博利珠单抗治疗的高危III期黑色素瘤患者中,免疫相关不良事件的发生与更长的无复发生存相关。

研究设计与样本

  • 双盲EORTC 1325/KEYNOTE-054临床试验的二次分析,纳入1019例完全切除的III期黑色素瘤成人患者,按1:1随机接受帕博利珠单抗200mg每3周共18次或安慰剂治疗。

主要发现

  • 帕博利珠单抗组irAE发生率为37.4%(190/509),安慰剂组为9.0%(45/502),男女发生率相似。
  • 在开始治疗的患者中,帕博利珠单抗组RFS较安慰剂组更长(HR 0.56, 98.4%CI 0.43-0.74)。

临床怎么用

  • 在接受帕博利珠单抗辅助治疗的III期黑色素瘤患者中,发生irAE可能提示更好的无复发生存,但需监测和管理毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. OBJECTIVE: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma. DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo. Eligible patients were adults 18 years and older with complete resection of cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1 micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit metastasis) cancer. Patients were randomized from August 26, 2015, to November 14, 2016. The clinical cutoff for the data set was October 2, 2017. Analyses were then performed on the database, which was locked on November 28, 2017. INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately 1 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The association between irAEs and RFS was estimated using a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a value of 0 before irAE onset and 1 after irAE onset. RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older. Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4% CI, 0.43-0.74) among patients who started treatment. The incidence of irAEs was 190 (37.4%) in the pembrolizumab arm (n = 509) and 45 (9.0%) in the placebo arm (n = 502); in each treatment group, the incidence was similar for men and women. The occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR, 0.61; 95% CI, 0.39-0.95; P = .03) in both men and women. However, in the placebo arm, this association was not significant. Compared with the placebo arm, the reduction in the hazard of recurrence or death in the pembrolizumab arm was greater after the onset of an irAE than without or before an irAE (HR, 0.37; 95% CI, 0.24-0.57 vs HR, 0.61; 95% CI, 0.49-0.77, respectively; P = .03). CONCLUSIONS AND RELEVANCE: In this study, the occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm. TRIAL REGISTRATIONS: ClinicalTrials.gov identifier: NCT02362594; EudraCT identifier: 2014-004944-37.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Eggermont AMM, Kicinski M, Blank CU, et al. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 31895407. doi:10.1001/jamaoncol.2019.5570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。